Different Mutations May Predict Different Responses to Chemotherapy
By LabMedica International staff writers Posted on 21 Dec 2015 |
Image: Immunohistochemistry of estrogen receptor (ER)-positive (brown), in metastatic breast cancer (Photo courtesy of Dr. Steven Halls).
Among patients with estrogen receptor (ER)-positive, metastatic breast cancer, those who had a D538G and/or a Y537S mutation in the estrogen receptor 1 (ESR1) gene, as detected in cell-free DNA obtained from patient blood samples, had significantly worse median overall survival.
Results from clinical trial showed that adding everolimus to the standard hormonal therapy exemestane improved outcomes for postmenopausal women with ER-positive, locally advanced or metastatic breast cancer that has progressed after treatment with an aromatase inhibitor.
Scientists at the Memorial Sloan Kettering Cancer Center (New York, NY, USA) evaluated blood samples from 541 of the 724 patients enrolled in BOLERO-2 clinical trial. They detected the D538G ESR1 mutation in samples from 83 patients, the Y537S ESR1 mutation in samples from 42 patients, and both mutations in samples from 30 patients.
Median overall survival was 32.1 months for patients with neither a D538G nor the Y537S ESR1 mutation, 26 months for those with only a D538G mutation, 20 months for those with only a Y537S mutation, and 15.2 months for those with both mutations. Exploratory analyses showed that adding everolimus to exemestane more than doubled progression-free survival for patients with neither ESR1 mutation and for those with a D538G mutation. However, the treatment combination did not appear to increase progression-free survival for patients with a Y537S mutation.
Sarat Chandarlapaty, MD, PhD, a medical oncologist, said, “Using a simple blood test, we found that the D538G and Y537S mutations in the estrogen receptor are more common in patients with advanced, ER-positive breast cancer than previously appreciated and that patients with these mutations don't respond as well to currently used therapies and die from their disease sooner than patients who do not have these mutations.” The study was presented on December 10, 2015, at the San Antonio Breast Cancer Symposium held in San Antonio (TX, USA).
Related Links:
Memorial Sloan Kettering Cancer Center
Results from clinical trial showed that adding everolimus to the standard hormonal therapy exemestane improved outcomes for postmenopausal women with ER-positive, locally advanced or metastatic breast cancer that has progressed after treatment with an aromatase inhibitor.
Scientists at the Memorial Sloan Kettering Cancer Center (New York, NY, USA) evaluated blood samples from 541 of the 724 patients enrolled in BOLERO-2 clinical trial. They detected the D538G ESR1 mutation in samples from 83 patients, the Y537S ESR1 mutation in samples from 42 patients, and both mutations in samples from 30 patients.
Median overall survival was 32.1 months for patients with neither a D538G nor the Y537S ESR1 mutation, 26 months for those with only a D538G mutation, 20 months for those with only a Y537S mutation, and 15.2 months for those with both mutations. Exploratory analyses showed that adding everolimus to exemestane more than doubled progression-free survival for patients with neither ESR1 mutation and for those with a D538G mutation. However, the treatment combination did not appear to increase progression-free survival for patients with a Y537S mutation.
Sarat Chandarlapaty, MD, PhD, a medical oncologist, said, “Using a simple blood test, we found that the D538G and Y537S mutations in the estrogen receptor are more common in patients with advanced, ER-positive breast cancer than previously appreciated and that patients with these mutations don't respond as well to currently used therapies and die from their disease sooner than patients who do not have these mutations.” The study was presented on December 10, 2015, at the San Antonio Breast Cancer Symposium held in San Antonio (TX, USA).
Related Links:
Memorial Sloan Kettering Cancer Center
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer